axelvento
dCellVax
- Registrato
- 21/12/04
- Messaggi
- 16.246
- Punti reazioni
- 419
igxt
- Creatore Discussione axelvento
- Data di inizio
axelvento
dCellVax
- Registrato
- 21/12/04
- Messaggi
- 16.246
- Punti reazioni
- 419
Ma sei un veggente???? Hai indovinato la cavalcata alla grande.....
Altri titoli che ritieni interessanti??
Conosci acura pharma?
axelvento
dCellVax
- Registrato
- 21/12/04
- Messaggi
- 16.246
- Punti reazioni
- 419
axelvento
dCellVax
- Registrato
- 21/12/04
- Messaggi
- 16.246
- Punti reazioni
- 419
rio tinto
Nuovo Utente
- Registrato
- 1/11/09
- Messaggi
- 733
- Punti reazioni
- 31
...ne andasse bene una.....
rio tinto
Nuovo Utente
- Registrato
- 1/11/09
- Messaggi
- 733
- Punti reazioni
- 31
La FDA afferma che 'A ripresentazione di un'applicazione o integratore di efficacia che la FDA classifica come classe 1 ripresentazione costituisce un accordo da parte del richiedente di avviare un nuovo ciclo di revisione 2 mesi a partire dalla data FDA riceve la ripresentazione " Questo sembra essere un Classe 1 Classe 2 che vorrebbe dati, più informazioni di sicurezza, ecc Hanno detto che riceveranno le informazioni a loro in settimane. Una volta che ottengono le informazioni per loro la FDA far sapere loro hanno avuto poi si inizierà la revisione 2 mesi ciclo.
Secondo la vs. opinione che tempi prevedete?
Secondo la vs. opinione che tempi prevedete?
axelvento
dCellVax
- Registrato
- 21/12/04
- Messaggi
- 16.246
- Punti reazioni
- 419
da non dimenticare la bestia...
.94
IntelGenx Announces Receipt of Two Additional U.S. Patent Allowances Related to Proprietary Technology
Saint Laurent, Quebec--(Newsfile Corp. - February 26, 2014) - IntelGenx Corp. (TSXV: IGX) (OTCQX: IGXT) ("IntelGenx"), a Canadian drug delivery company focusing on oral drug delivery, today announced that it has received a Notice of Allowance ("NOA") from the United States Patent and Trademark Office for U.S. Patent Application Serial No. 11/647,033 entitled "Multilayer tablet" which covers the technology used in our hypertension product currently under development. A second NOA has been received for U.S. Patent Application Serial No. 11/782,838 entitled "Controlled-release pharmaceutical tablets" which is related to the drug delivery technology used in Forfivo XL®, IntelGenx' first FDA-approved product currently commercialized in the U.S. These two NOA's conclude the examination of each U.S. patent application and will result in the issuance of two U.S. patents after administrative processes are completed.
"These two additional NOA's in the U.S. represent yet another important expansion of IntelGenx' patent estate as well as demonstrating the innovative design of our drug delivery technologies" said Rajiv Khosla, IntelGenx' President and Chief Executive Officer. "Our goal is to protect the innovation and commercial potential of the products developed at IntelGenx and these NOA's further strengthen our proprietary position."
About IntelGenx:
IntelGenx is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. IntelGenx uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastrointestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. IntelGenx' development pipeline includes products for the treatment of indications such as severe depression, hypertension, erectile dysfunction, migraine, insomnia, CNS indications, idiopathic pulmonary fibrosis, oncology and pain, as well as animal health products. More information is available about the company at IntelGenX.
.94
IntelGenx Announces Receipt of Two Additional U.S. Patent Allowances Related to Proprietary Technology
Saint Laurent, Quebec--(Newsfile Corp. - February 26, 2014) - IntelGenx Corp. (TSXV: IGX) (OTCQX: IGXT) ("IntelGenx"), a Canadian drug delivery company focusing on oral drug delivery, today announced that it has received a Notice of Allowance ("NOA") from the United States Patent and Trademark Office for U.S. Patent Application Serial No. 11/647,033 entitled "Multilayer tablet" which covers the technology used in our hypertension product currently under development. A second NOA has been received for U.S. Patent Application Serial No. 11/782,838 entitled "Controlled-release pharmaceutical tablets" which is related to the drug delivery technology used in Forfivo XL®, IntelGenx' first FDA-approved product currently commercialized in the U.S. These two NOA's conclude the examination of each U.S. patent application and will result in the issuance of two U.S. patents after administrative processes are completed.
"These two additional NOA's in the U.S. represent yet another important expansion of IntelGenx' patent estate as well as demonstrating the innovative design of our drug delivery technologies" said Rajiv Khosla, IntelGenx' President and Chief Executive Officer. "Our goal is to protect the innovation and commercial potential of the products developed at IntelGenx and these NOA's further strengthen our proprietary position."
About IntelGenx:
IntelGenx is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. IntelGenx uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastrointestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. IntelGenx' development pipeline includes products for the treatment of indications such as severe depression, hypertension, erectile dysfunction, migraine, insomnia, CNS indications, idiopathic pulmonary fibrosis, oncology and pain, as well as animal health products. More information is available about the company at IntelGenX.
da non dimenticare la bestia...
Ma stai parlando di me
IntelGenx Technologies Corp. (IGXT) a Canadian drug delivery company paying attention on oral drug delivery, today announced, together with RedHill Biopharma Ltd. (RDHL) an emerging Israeli biopharmaceutical organization focused mostly on the progress and acquisition of late clinical-stage drugs, that they submitted a response to the Complete Response Letter (“CRL”) of the U.S. Food and Drug Administration for the New Drug Application for their VersaFilmOral Film Product for the treatment of acute migraines.
axelvento
dCellVax
- Registrato
- 21/12/04
- Messaggi
- 16.246
- Punti reazioni
- 419
da non dimenticare la bestia...
Ma stai parlando di me
IntelGenx Technologies Corp. (IGXT) a Canadian drug delivery company paying attention on oral drug delivery, today announced, together with RedHill Biopharma Ltd. (RDHL) an emerging Israeli biopharmaceutical organization focused mostly on the progress and acquisition of late clinical-stage drugs, that they submitted a response to the Complete Response Letter (“CRL”) of the U.S. Food and Drug Administration for the New Drug Application for their VersaFilmOral Film Product for the treatment of acute migraines.
ma tu sei un fiorellino
di montagna
appena sbocciato
fresca fresca
axelvento
dCellVax
- Registrato
- 21/12/04
- Messaggi
- 16.246
- Punti reazioni
- 419
siamo in attesa....
.935
https://eresearch.fidelity.com/eres...rovider=PRIMZONE&product=FULLFEED&hlinks=vnhl
.935
https://eresearch.fidelity.com/eres...rovider=PRIMZONE&product=FULLFEED&hlinks=vnhl
